In addition to our observations, loss of the Interleukin 9 receptor (IL9R) locus was previously observed in three out of seven relapsed DLBCL cases [15], and STAT6 mutations were reported in 36% of R/R GCB-type DLBCL [18], both further implicating a role for the JAK-STAT pathway in relapse. This evidence concerns the gene IL9R and diffuse large B-cell lymphoma.